Product Citations for Neurodegenerative Proteins

StressMarq’s proteins for neurodegenerative disease research (monomers, pre-formed fibrils and oligomers) have been cited in many peer-reviewed scientific journals. Here is a chronological list of product citations for StressMarq’s alpha synuclein, tau, and amyloid beta. To see a complete list of all citations for a product, please refer to the product-specific webpage.

Quickly jump to Tau Citations

Quickly jump to Amyloid Beta Citations

Alpha Synuclein Citations

 [Newest – Oldest]

  • Facile generation of drug-like conformational antibodies specific for amyloid fibrils. Desai, A.A. et al. Nat Chem Biol. May 2025.
    • Catalog# SPR-317: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
    • Catalog# SPR-332: Human Recombinant N-Terminal Acetylated Alpha Synuclein Pre-formed Fibrils (Type 1)
    • Catalog# SPR-484: Human Recombinant Alpha Synuclein Oligomers (Kinetically Stable)
  • Astrocytes carrying LRRK2 G2019S exhibit increased levels of clusterin chaperone via miR-22-5p and reduced ability to take up α-synuclein fibrils. Filippini, A. et al. Acta Neuropathol Commun. May 2025.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Retinoid X receptor as a therapeutic target to treat neurological disorders associated with α-synucleinopathy. Zhylkibayev, A. et al. Cells. May 2025.
  • Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform. Schuler, M. et al. EMBO Mol Med. Apr 2025.
  • Trehalose-releasing nanogels reduce α-synuclein-induced Lewy body-like inclusions in primary mouse hippocampal neurons. Maruf, A. et al. J Mater Chem B. Apr 2025.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Astrocytic RNA editing regulates the host immune response to alpha-synuclein. D’Sa, K. et al. Sci Adv. Apr 2025.
  • Peptidomimetics activating the proteasome: A new perspective for Parkinson’s treatment. Trepczyk, K. et al. J Med Chem. Apr 2025.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • A single-molecule liposome assay for membrane permeabilisation. Bąk, K.M. et al. Angew Chem Int Ed Engl. Apr 2025.
  • Leucine-rich repeat kinase 2 promotes disintegration of retinal pigment epithelial cell: Implication in the pathogenesis of dry age-related macular degeneration. Suimon, Y. et al. Am J Pathol [Preproof]. Apr 2025.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Myeloid FtH regulates macrophage response to kidney injury by modulating Snca and ferroptosis. Chatterjee, T. et al. bioRxiv [Preprint]. Mar 2025.
    IHC of Sprague-Dawley rat brain injected with Type 1 human alpha synuclein Pre-formed Fibrils (SPR-322)

    Immunohistochemistry analysis of Female Sprague-Dawley Rat brain injected with Human Alpha Synuclein Pre-formed Fibrils (Type 1) (catalog# SPR-322).

  • A 3D gut-brain-vascular platform for bidirectional crosstalk in gut-neuropathogenesis. Cho, H. et al. Research Square [Preprint]. Mar 2025.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Targeting the ClpP-αSynuclein interaction with a decoy peptide to mitigate neuropathology in Parkinson’s disease models. Hu, D. et al. bioRxiv [Preprint]. Feb 2025.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Glucosylceramide induced ectosomes propagate pathogenic α-synuclein in Parkinson’s disease. Jacquemyn, J. et al. bioRxiv [Preprint]. Feb 2025.
  • Cholesterol-mediated lysosomal dysfunction in APOE4 astrocytes promotes α-synuclein pathology in human brain tissue. Mesentier-Louro, L. A. et al. bioRxiv [Preprint].  Feb 2025.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
Alpha Synuclein Pre-formed Fibrils (PFF), Type 1 (cat#SPR-322) and Type 2 (cat#SPR-317) do have small secondary structure differences.

UV-CD data comparing StressMarq’s Alpha Synuclein Type 1 (catalog# SPR-322) and Type 2 (catalog# SPR-317) PFFs. Both have a high beta sheet/turn content, with small secondary structure differences.

  • 14-3-3θ phosphorylation exacerbates alpha-synuclein aggregation and toxicity. Wang, B. et al. Neurobiol Dis [Preproof]. Jan 2025.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Parkinson disease-associated toxic exposures selectively upregulate vesicular glutamate transporter vGlut2 in a model of human cortical neurons. Clark, K. A. et al. Mol Biol Cell. Jan 2025.
  • From literature identification to efficient validation of targets – effects on alpha-synuclein aggregation in cortical neurons. Orrhult, L.S. et al. Cellectricon [Sweden]. Nov 2024.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005). Fukumoto, H. et al. FASEB J. Nov 2024.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
    • Catalog# SPR-484: Human Recombinant Alpha Synuclein Oligomers (Kinetically Stable)
  • Exploring the potential of biomimetic peptides in targeting fibrillar and filamentous alpha-synuclein — An in silico and experimental approach to Parkinson’s disease. Frantzeskos, S. A. et al. Biomimetics. Nov 2024.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • STAT3 inhibitor increases α-synuclein in PFF-treated astroglia cells by dysregulating autophagy and potentially affects exosome biogenesis. Luo, Y. et al. Neuromolecular Med. Oct 2024.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)

      Thioflavin T Assay for SPR-322-A594

      Thioflavin T seeding assay. Alpha Synuclein Pre-formed Fibrils (Type 1) conjugated to ATTO 594 (catalog# SPR-322-A594) show similar seeding capabilities as unconjugated Alpha Synuclein PFFs (catalog# SPR-322).

  • A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. An, S. et al. bioRxiv [Preprint]. Oct 2024.
  • PDCD4 triggers α-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson’s disease. Cao, B. et al. NPJ Parkinsons Dis. Aug 2024.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Low-density lipoprotein receptor-related protein 1 mediates α-synuclein transmission from the striatum to the substantia nigra in animal models of Parkinson’s disease. Luo, H. et al. Neural Regen Res. July 2024.
  • Gut microbiota produces biofilm-associated amyloids with potential for neurodegeneration. Fernández-Calvet, A. et al. Nature Communications. May 2024.
StressMarq’s Alpha Synuclein PFFs (red) cat#SPR-322, were shown to be taken up by SH-SY5Y cells and transmitted to neuronal iPSCs within 14 days.

StressMarq’s Human Alpha Synuclein Pre-formed Fibrils (Type 1) (red), catalog# SPR-322, were shown to be taken up by SH-SY5Y cells and transmitted to neuronal iPSCs within 14 days. Blue: Hoechst/DNA; Green: SHSY5Y-GFP; Red: SPR-322; Purple: Tubulin.

  • Identification of glycerol 3-phosphate acyltransferase as a potent modifier of α-synuclein-induced toxicity. Lim, K.L. et al. Research Square [Preprint]. Apr 2024.
  • Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy. Parmasad, J.L. et al. Cell Death Dis. Mar 2024.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • FABP2 is involved in intestinal α-synuclein pathologies. Sekimori, T. et al. J Integr Neurosci. Feb 2024. 
  • C-terminally truncation is a prominent post-translational modification of human erythrocyte α-synuclein. Amagai, R. et al.   J Biochem. Feb 2024.
    • Catalog# SPR-331: Human Recombinant N-Terminal Acetylated Alpha Synuclein Monomers (Type 1)
  • Immunization effects of  a novel α-synuclein-based peptide epitope vaccine in Parkinson’s disease-associated pathology. Park, J. S. et al. Vaccines. Dec 2023.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Fluorescent peptide-based probe for the detection of alpha-synuclein aggregates in the gut. Sim, R. et al. bioRxiv [Preprint]. Nov 2023.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)

      IHC of Sprague-Dawley rat brain injected with Type 1 mouse alpha synuclein Pre-formed Fibrils (SPR-324)

      Immunohistochemistry analysis of rat brain injected with Mouse Alpha Synuclein Pre-formed Fibrils (Type 1) (catalog# SPR-324). Species: Female Sprague-Dawley Rat. Alpha synuclein pathology is seen in the periform/insular cortex and the cingulate cortex on both the same (ipsi) and opposite (contra) sides as the injection sites.

  • Two-color coincidence single-molecule pulldown for the specific detection of disease-associated protein aggregates. Saleeb, R.S. et al. Sci Adv. Nov 2023.
  • α-Synuclein-dependent increases in PIP5K1γ drive inositol signaling to promote neurotoxicity. Horvath, J.D. et al. Cell Rep. Oct 2023.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • A novel NOX inhibitor alleviates Parkinson’s disease pathology in PFF-injected mice. Ofori, K. et al. Int J Mol Sci. Sept 2023.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Mutant α-synuclein propagates via the lymphatic system of the brain in the monomeric state. Fujita, K. et al. Cell Rep. Aug 2023.
    • Catalog# SPR-325: Human Recombinant A53T Mutant Alpha Synuclein Monomers (Type 1)
  • Targeted degradation of α-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology. Lee, J. et al. Mol Neurodegener. Jun 2023.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease. Nim, S. et al. Nat Commun. Apr 2023.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)

      TEM of Human Recombinant Alpha Synuclein Oligomers (Kinetically Stable) (SPR-484).

      TEM of Human Alpha Synuclein Oligomers (Kinetically-Stable) (catalog# SPR-484).

  • Aggregation of alpha-synuclein in enteric neurons does not impact function in vitro. Bindas, A.J. et al. Sci Rep. Dec 2022.
  • Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology. Jorge-Oliva, M. et al. Alzheimers Res Ther. Dec 2022.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Observation of α-synuclein preformed fibrils interacting with SH-SY5Y neuroblastoma cell membranes using scanning ion conductance microscopy. Feng, C. et al. ACS Chem Neurosci. Dec 2022.
    • Catalog# SPR-317: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 2)
  • Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson’s disease. Cho, E. et al. Neurobiol Dis. Dec 2022.
    • Catalog# SPR-326: Human Recombinant A53T Mutant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • LRP1 is a neuronal receptor for α-synuclein uptake and spread. Chen, K. et al. Mol Neurodegener. Sept 2022
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
    • Catalog# SPR-484: Human Recombinant Alpha Synuclein Oligomers (Kinetically Stable)
  • Rational generation of monoclonal antibodies selective for pathogenic forms of alpha-synuclein. Gibbs, E. et al. Biomedicines. Sept 2022.
    Mouse Type 1 alpha synuclein Pre-formed Fibrils (SPR-324) seed the formation of new alpha Synuclein fibrils from the pool of alpha synuclein monomers (SPR-323) as shown by increased fluorescence intensity by Thioflavin T over time.

    Thioflavin T seeding assay. Mouse Alpha Synuclein Pre-formed Fibrils (Type 1) (catalog# SPR-324) seed the formation of new alpha synuclein fibrils from the pool of Mouse Alpha Synuclein Monomers (Type 1) (catalog#SPR-323).

    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • A novel NOX inhibitor treatment attenuates Parkinson’s disease-related pathology in mouse models. Ghosh, A.A. Int J Mol Sci. Apr 2022.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Cell culture media, unlike the presence of insulin, affect α-synuclein aggregation in dopaminergic neurons. Hlushchuk, I. et al. Biomolecules. Apr 2022.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Design, synthesis and chemically engineered graphene quantum dot applications: contrast agent for MR imaging and targeted therapeutics on Parkinson’s treatment. Poonkuzhali, K. et al. SSRN. Mar 2022.
    • Catalog# SPR-322: Human Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Heat shock protein 70 as a sex-skewed regulator of α-synucleinopathy. Bhatia, T.N. et al. Neurotherapeutics. Oct 2021
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Alpha-synuclein preformed fibrils induce cellular senescence in Parkinson’s disease models. Verma, D.K. et al. Cells. Jul 2021.
  • Domain-independent inhibition of CBP/p300 attentuates α-synuclein aggregation. Hlushchuk, I. et al. ACS Chem Neurosci. Jul 2021.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Reelin alleviates mesenchymal stem cell senescence and reduces pathological α-synuclein expression in an in vitro model of Parkinson’s disease. Cho, E. et al. Genes (Basel). Jul 2021.
    • Catalog# SPR-326: Human Recombinant A53T Mutant Alpha Synuclein Pre-formed Fibrils (Type 1)
  • Suppression of aggregate and amyloid formation by a novel intrinsically disordered region in metazoan Hsp110 chaperones. Yakubu, U.M et al. J Biol Chem. Mar 2021.
  • The SUMO conjugase Ubc9 protects dopaminergic cells from cytotoxicity and enhances the stability of α-synuclein in Parkinson’s disease models. Verma, D.K. et al. eNeuro. Sept 2020.
    • Catalog# SPR-324: Mouse Recombinant Alpha Synuclein Pre-formed Fibrils (Type 1)

 

 

 

Tau Citations

 [Newest – Oldest] 

  • Facile generation of drug-like conformational antibodies specific for amyloid fibrils. Desai, A.A. et al. Nat Chem Biol. May 2025.
    • Catalog# SPR-329: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils
    • Catalog# SPR-330: Human Recombinant Tau (K18) P301L Mutant Pre-formed Fibrils
    • Catalog# SPR-475: Mouse Recombinant Tau-430 (2N4R) P290S Mutant Pre-formed Fibrils (Human P301S Equivalent)
    • Catalog# SPR-491: Human Recombinant Tau-352 (fetal 0N3R) Wild-Type Pre-formed Fibrils
  • Detection of misfolded proteins in neurodegenerative disease models with a highly sensitive chemiluminescence probe. Zhu, B. et al. bioRxiv [Preprint]. Apr 2025.
  • Macropinocytosis of aggregated amyloid-beta and tau requires Arf6 and the RhoGTPases Rac1, Cdc42 and RhoA. Krupa, J. et al. bioRxiv [Preprint]. Mar 2025.

    TEM of Human Recombinant Tau-441 (2N4R) P301S Mutant Protein Filaments (catalog# SPR-463).

  • Seed structure and phosphorylation in the fuzzy coat impact tau seeding competency. Kasen, A. et al. bioRxiv [Preprint]. Mar 2025.
  • Temperature-dependent aggregation of tau protein is attenuated by native PLGA nanoparticles under in vitro conditions. Sil Paul, P. et al. Int J Nanomedicine. Feb 2025.
    • Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Pre-formed Fibrils
  • A novel IncRNA FAM151B-DT regulates autophagy and degradation of aggregation prone proteins. Renganathan, A. et al. medRxiv [Preprint]. Jan 2025.
    • Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Pre-formed Fibrils
  • Reversal of neuronal tau pathology via adiponectin receptor activation. McGregor, E. R. et al. Commun Biol. Jan 2025.
    • Catalog# SPR-329: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils
  • Parkinson disease-associated toxic exposures selectively upregulate vesicular glutamate transporter vGlut2 in a model of human cortical neurons. Clark, K. A. et al. Mol Biol Cell. Jan 2025.
    Thioflavin T emission curves show increased fluorescence (correlated to tau aggregation) when tau Pre-formed fibrils (SPR-329) are combined with tau monomers (SPR-327). The Pre-formed fibrils seed the formation of new fibrils from a pool of monomers.

    Thioflavin T seeding assay. Tau-441 (2N4R) P301S Mutant PFFs (catalog# SPR-329) seed the formation of new tau fibrils from the pool of  corresponding monomers (catalog# SPR-327).

    • Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Pre-formed Fibrils
  • Microglia internalize tau monomers and fibrils using distinct receptors but similar mechanisms. Falkon, K. F. et al. Alzheimers Dement. Dec 2024.
  • Thonningianin A from Penthorum chinense Pursh as a targeted inhibitor of Alzheimer’s disease-related β-amyloid and Tau proteins. Yu, L. et al. Phytother Res. Sept 2024.
  • FGFR3 drives Aβ-induced tau uptake. Kim, D. et al. Exp Mol Med. July 2024.
  • Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy. Toral-Rios, D. et al. J Exp Med. Apr 2024.
    • Catalog# SPR-329-A488: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils: ATTO 488
    • Catalog# SPR-471: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils (Baculovirus/Sf9)
  • BAG3 regulates the specificity of the recognition of specific MAPT species by NBR1 and SQSTM1. Lin, H. et al. Autophagy. Mar 2024.

    TEM of Human Recombinant Tau-441 (2N4R), Wild-Type Pre-formed Fibrils (catalog# SPR-480).

    • Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Pre-formed Fibrils
  • Reduced proganulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase. Takahashi, H. et al. Nat Commun. Feb 2024.
  • ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Eisenbaum, M. et al. Glia. Jan 2024.
  • APOE3ch alters microglial spread and suppresses Aβ-induced seeding and spread. Chen, Y. et al. Cell. Jan 2024.
    • Catalog# SPR-329: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils
  • Complement receptor 4 mediates the clearance of extracellular tau fibrils by microglia. Yoo, C. et al. Research Square [Preprint]. Nov 2023.
  • α-Synuclein-dependent increases in PIP5K1γ drive inositol signaling to promote neurotoxicity. Horvath, J.D. et al. Cell Rep. Oct 2023.
    • Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Pre-formed Fibrils

      SPR-330 Tau Preformed Fibrils Protein IHC

      Immunohistochemistry analysis of P301L mouse hippocampus injected with Human Recombinant Tau (K18) P301L Mutant Pre-formed Fibrils (catalog# SPR-330).

  • A human neuron/astrocyte co-culture to model seeded and spontaneous intraneuronal tau aggregation. Batenburg, K.L. et al. Curr Protoc. Oct 2023.
  • In vivo near-infrared fluorescence imaging selective for soluble amyloid beta aggregates using y-shaped BODIPY derivative. Akasaka, T. et al. J Med Chem. Oct 2023.
    • Catalog# SPR-477: Human Recombinant Tau (K18) Delta K280 Mutant Pre-formed Fibrils
  • Polarized microtubule remodeling transforms the morphology of reactive microglia and drives cytokine release. Adrian, M. et al. Nat Commun. Oct 2023.
    • Catalog# SPR-471: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils (Baculovirus/Sf9)
    • Catalog# SPR-479: Human Recombinant Tau-441 (2N4R) Wild-Type Monomers
  • Increased G3BP2-tau interaction in tauopathies is a natural defense against tau aggregation.Wang, C. et al. Neuron. Sept 2023.
    • Catalog# SPR-329-A488: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils: ATTO 488
    • Catalog# SPR-471: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils (Baculovirus/Sf9)
  • Quantitative flow cytometric selection of tau conformational antibodies specific for pathological aggregates. Zupancic, J.M. et al. Front Immunol. Aug 2023.
    SPR-461_Tau-Preformed-Fibrils-Protein-TEM

    TEM of Human Recombinant Truncated Tau Fragment (AA297-391) (dGAE) Pre-formed Fibrils (catalog# SPR-461).

    • Catalog# SPR-329: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils
    • Catalog# SPR-461: Human Recombinant Truncated Tau Fragment (AA297-391) (dGAE) Pre-formed Fibrils
  • Mutant β1-adrenergic receptor improves REM sleep and ameliorates tau accumulation in a mouse model of tauopathy. Dong, Q. et al. PNAS. Apr 2023.
  • A phosphoinositide signalling pathway mediates rapid lysosomal repair. Tan, J.X. & Finkel, T. Nature. Sept 2022.
  • Exosomal tau with seeding activity is released from Alzheimer’s disease synapses, and seeding potential is associated with amyloid beta. Miyoshi, E. et al. Lab Invest. Dec 2021.
    • Catalog# SPR-475: Mouse Recombinant Tau-430 (2N4R) P290S Mutant Pre-formed Fibrils (Human P301S Equivalent)
  • Astrocyte senescence and SASP in neurodegeneration: tau joins the loop. Ungerleider, K. et al. Cell Cycle. Apr 2021.
    • Catalog# SPR-444: Human Recombinant Truncated Tau Fragment (AA297-391) (dGAE) Monomers
    • Catalog# SPR-461: Human Recombinant Truncated Tau Fragment (AA297-391) (dGAE) Pre-formed Fibrils
  • Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology. Sandusky-Beltran, L.A. et al. J Clin Invest. Feb 2021.
  • Cornel iridoid glycoside regulates modification of tau and alleviates synaptic abnormalities in aged P301S mice. Yang, C. et al. Curr Med Sci. Dec 2020.

 

Amyloid Beta Citations

AFM of Human Synthetic Amyloid Beta 1-42 Pre-formed Fibrils (catalog# SPR-487).

[Newest – Oldest]

  • Advanced Alzheimer’s disease models using iPSC-derived microglia and neurons harboring disease-related gene variants. Shatri, E.B. et al. Bioneer [Denmark]. Apr 2025.
  • The Alzheimer’s disease gene SORL1 regulates lysosome function in the human microglia. Mishra, S. et al. bioRxiv [Preprint]. Jan 2025.
  • High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005). Fukumoto, H. et al. FASEB J. Nov 2024.
  • Hybrid amyloid quantum dot nano-bio assemblies to probe neuroinflammatory damage. Chiang, W. et al. ACS Chem Neurosci. Aug 2024.
  • Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease. Mao, H. et al. Transl Neurodegener. Jul 2024.
  • Chimeric antigen receptor macrophages target and resorb amyloid plaques. Kim, A.B. et al. JCI Insight. Mar 2024.

    TEM of Human Synthetic Amyloid Beta 1-42 Oligomers (catalog# SPR-488).

  • α-Synuclein-dependent increases in PIP5K1γ drive inositol signaling to promote neurotoxicity. Horvath, J.D. et al. Cell Rep. Oct 2023.